Alkermes
265 Olinger Circle
Wilmington
OH
45177
United States
Tel: 937655-4441
13 articles about Alkermes
-
After being criticized earlier this month by U.S. Sen. Kamala Harris, three separate sexual harassment lawsuits have been reported.
-
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
-
Alkermes’ NDA for Investigational Product Designed for Initiation Onto ARISTADA Accepted for Filing by U.S. FDA
11/16/2017
FDA action is expected by June 30, 2018.
-
Alkermes' VIVITROL and Value of Medication-Assisted Treatment for Opioid Dependence Featured in Study Sponsored by National Institute on Drug Abuse
11/15/2017
This is the second study published in the past month comparing these two medications and it provides additional evidence supporting the use of VIVITROL as an effective treatment option for patients.
-
Alkermes Reveals Recipients of the 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders
11/9/2017
Alkermes announced the company awarded $1 million in grants to national and local non-profit community organizations for the implementation of innovative, high-impact and replicable programs designed to support people affected by mental health and substance use disorders.
-
Alkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid Dependence
11/9/2017
The goal of this review should be to establish a shared national understanding of the characteristics of these medicines and the scientific and medical evidence supporting their use.
-
Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
11/8/2017
A poster on the preclinical data, titled, “A Novel, Individualized Xenograft Model of Cancer Immunotherapy and Tumor Growth Inhibition by ALKS 4230,” will be presented by Dr. Brian Gastman of the Cleveland Clinic at SITC in National Harbor, Md. on Friday, Nov. 10, 2017 (Poster #P351).
-
Harris fired the first shots on Monday.
-
Alkermes Presents Data Demonstrating Safety and Gastrointestinal Tolerability Profile of ALKS 8700 for the Treatment of Multiple Sclerosis
10/30/2017
Interim data from more than 570 patients at one and three months of treatment with ALKS 8700 were presented at MSParis2017.
-
Alkermes Unveils Investigational Product Designed for Initiation Onto Aristada for Treatment of Schizophrenia
10/26/2017
Alkermes plc unveiled Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD), a novel, investigational product designed for initiation onto ARISTADA (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
-
Alkermes to Initiate New Clinical Study Evaluating Aristada and Invega Sustenna for the Treatment of Schizophrenia
10/26/2017
Alkermes plc today announced plans to initiate a phase 3b clinical study to evaluate the efficacy and safety of ARISTADA (aripiprazole lauroxil) extended-release injectable suspension and INVEGA SUSTENNA (paliperidone palmitate) in patients experiencing an acute exacerbation of schizophrenia.
-
Alkermes plc Reports Third Quarter 2017 Financial Results
10/26/2017
Alkermes plc today reported financial results for the third quarter of 2017.
-
New Study Comparing Effectiveness of Alkermes' Extended-Release Naltrexone to Buprenorphine-Naloxone for Opioid Dependence Published in JAMA Psychiatry
10/19/2017
Results were published this week in the Journal of the American Medical Association Psychiatry.